tabalumab: Clinical Trials

8 trials of tabalumab, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

7 completed, 1 terminated. 8 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 28Completed 7, Terminated 1

Follow tabalumab: new trials by email Literature Review of tabalumab trials Research Report on tabalumab

Trials (filtered) newest first · largest first

All 8 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM)
Placebo, Dexamethasone, Bortezomib - Multiple Myeloma
Phase 2CompletedEli Lilly and Company2202012-07-012019-10-08
A Study of LY2127399 in Rheumatoid Arthritis
LY2127399 - Rheumatoid Arthritis
Phase 2TerminatedEli Lilly and Company22012-05-012018-04-26
A Study in Participants With End-Stage Renal Disease
LY2127399 - Kidney Failure, Chronic
Phase 2CompletedEli Lilly and Company182011-04-012018-05-14
A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
LY2127399, Placebo - Relapsing-Remitting Multiple Sclerosis
Phase 2CompletedEli Lilly and Company2452009-04-012018-11-15
An Open Label Extension Study in Participants With Rheumatoid Arthritis
LY2127399 - Rheumatoid Arthritis
Phase 2CompletedEli Lilly and Company1822009-02-012018-04-25
A Study for Patients With Active Rheumatoid Arthritis Despite Ongoing Methotrexate Therapy
LY2127399, Placebo - Rheumatoid Arthritis
Phase 2CompletedEli Lilly and Company1582008-10-012018-07-10
A Study for Patients With Rheumatoid Arthritis on Methotrexate (MTX) With an Inadequate Response to TNFα Inhibitor Therapy
LY2127399, Placebo - Arthritis, Rheumatoid
Phase 2CompletedEli Lilly and Company1002008-06-012018-12-06
A Multi-Site Study to Evaluate the Safety and Effect of Study Drug on Participants With Rheumatoid Arthritis
LY2127399, Placebo - Arthritis, Rheumatoid
Phase 2CompletedEli Lilly and Company1362006-03-282019-09-10

Conditions studied

Arthritis, Rheumatoid (5)  ·  Arthritis (2)  ·  Kidney Failure, Chronic (1)  ·  Multiple Myeloma (1)  ·  Multiple Sclerosis (1)  ·  Multiple Sclerosis, Relapsing-Remitting (1)  ·  Recurrence (1)  ·  Sclerosis (1)  ·  Uremia (1)

Sponsors

Eli Lilly and Company (8)

Countries

United States (7)  ·  Germany (5)  ·  Poland (5)  ·  Mexico (4)  ·  Romania (4)  ·  Brazil (3)  ·  Canada (3)  ·  Hungary (3)  ·  Argentina (2)  ·  Australia (2)  ·  Austria (2)  ·  Belgium (2)  ·  Chile (2)  ·  France (2)  ·  India (2)

Results publications

PMID 23268367, PMID 23359344, PMID 23599435, PMID 25168268, PMID 26780484